Ipriflavone for the treatment of osteoporosis.
Choi
Y K
YK
Kyung-Hee University School of Medicine, Department of Internal Medicine, Seoul, Korea.
Han
I K
IK
Yoon
H K
HK
D000469:Alkaline Phosphatase / Q000097:blood; D015519:Bone Density / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects*; D001842:Bone and Bones / Q000187:drug effects; D002478:Cells, Cultured; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000097:blood / Q000517:prevention & control*; D013997:Time Factors
D007529:Isoflavones; D008055:Lipids; D015675:Osteocalcin; C018986:ipriflavone; D000469:Alkaline Phosphatase